Centurion Patentors as of February 11, 2025
Colette Song
Project Manager at Catalent Pharma Solutions.
Patent №: 12221626 – Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers. This invention relates to peptides, proteins, and cells for cancer immunotherapy, using tumor-associated T-cell epitopes to stimulate immune responses or activate T cells for patient treatment. These peptides can also be targets for antibodies and T-cell receptors.
Patent №: 12221468 – Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers. This invention relates to peptides, proteins, nucleic acids, and cells for cancer immunotherapy, focusing on tumor-associated T-cell epitopes used in vaccines or to activate T cells for patient treatment.
Patent №: 12221467 – Uterine cancer treatments. This invention relates to peptides, proteins, nucleic acids, and cells for cancer immunotherapy. It focuses on tumor-associated T-cell epitopes used in vaccines or to activate T cells for therapy, and as targets for antibodies and T-cell receptors.
Patent №: 12222631 – Flashlight.
Patent №: 12222629 – Follow focus.
Hyojin Lee
Principal Engineer at Samsung Electronics.
This disclosure relates to 5G/6G systems for higher data rates beyond 4G LTE. It describes a method where user equipment (UE) uses a neural network to transmit information, learns connection weights, sends updates to the base station, and adjusts its own network based on the learning results.
Centurion+ Patent Holders as of September 3, 2024
Centurion+ Patent Holders as of October 15, 2024
Inventor Recognitions with Centurion Plus Utility Patents as of September 5, 2023
About The Author
Angelina Kushnarova
Angelina Kushnarova (Sverediuk) was born in Ukraine. She graduated from Ternopil Medical University with a specialization in Medicine and completed an internship in Radiology at Lviv University. She worked as a Radiologist, while also working as a web developer.